home / stock / mdp:cc / mdp:cc quote
Last: | $2.31 |
---|---|
Change Percent: | 0.0% |
Open: | $2.31 |
Close: | $2.31 |
High: | $2.31 |
Low: | $2.3 |
Volume: | 3,802 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.31 | $2.31 | $2.31 | $2.31 | $2.3 | 3,802 | 08-02-2022 |
$2.8 | $2.89 | $2.8 | $2.89 | $2.8 | 7,810 | 05-06-2022 |
$2.81 | $3.04 | $2.81 | $3.04 | $2.79 | 15,089 | 05-05-2022 |
$3 | $3 | $3 | $3 | $2.94 | 17,475 | 05-04-2022 |
$3 | $3.03 | $3 | $3.03 | $2.97 | 22,222 | 05-03-2022 |
$3.01 | $3 | $3.01 | $3.04 | $2.97 | 13,628 | 05-02-2022 |
$3 | $3 | $3 | $3.04 | $3 | 6,310 | 04-29-2022 |
$3.02 | $3.05 | $3.02 | $3.05 | $2.98 | 20,657 | 04-28-2022 |
$3.01 | $3 | $3.01 | $3.06 | $2.98 | 9,490 | 04-27-2022 |
$3.03 | $3.01 | $3.03 | $3.03 | $2.99 | 6,570 | 04-26-2022 |
$2.99 | $3.02 | $2.99 | $3.03 | $2.95 | 12,334 | 04-25-2022 |
$3.05 | $3 | $3.05 | $3.1 | $2.95 | 29,297 | 04-22-2022 |
$2.99 | $3.1 | $2.99 | $3.11 | $2.95 | 16,980 | 04-21-2022 |
$3.04 | $3.15 | $3.04 | $3.15 | $3 | 43,089 | 04-20-2022 |
$3.16 | $3.18 | $3.16 | $3.18 | $3.05 | 27,176 | 04-19-2022 |
$3.16 | $3.21 | $3.16 | $3.24 | $3.15 | 18,055 | 04-18-2022 |
$3.19 | $3.2 | $3.19 | $3.21 | $3.18 | 18,921 | 04-15-2022 |
$3.19 | $3.2 | $3.19 | $3.21 | $3.18 | 18,921 | 04-14-2022 |
$3.21 | $3.23 | $3.21 | $3.23 | $3.2 | 5,568 | 04-13-2022 |
$3.17 | $3.17 | $3.17 | $3.21 | $3.17 | 12,797 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc. Company Name:
MDP:CC Stock Symbol:
TSXC Market:
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) to...